A2A Pharmaceuticals, Inc.'s Form 4 filing
Biomea Fusion, Inc. (BMEA) · filed Jun 2, 2023
- Accession no.
- 0001859061-23-000007
- Filed
- Jun 2, 2023
- Trade date
- May 31-Jun 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $4.26M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| A2A Pharmaceuticals, Inc.CIK 0001859061 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
A total of 75,000 shares were sold at an average price of 33.81 in multiple transactions ranging from 33.44 to 34.43. Details of the specific transactions are available upon request.
Referenced by the price of 1 transaction in Table I.
- F2
A total of 50,000 shares were sold at an average price of 34.5633 in multiple transactions ranging from 34.50 to 35.02 Details of the specific transactions are available upon request.
Referenced by the price of 1 transaction in Table I.